- Home
- ENTA vs FT Comparison
ENTA vs FT Comparison
Compare ENTA & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- FT
- Stock Information
- Founded
- ENTA 1995
- FT 1988
- Country
- ENTA United States
- FT United States
- Employees
- ENTA N/A
- FT N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- FT Trusts Except Educational Religious and Charitable
- Sector
- ENTA Health Care
- FT Finance
- Exchange
- ENTA Nasdaq
- FT Nasdaq
- Market Cap
- ENTA 164.6M
- FT 192.5M
- IPO Year
- ENTA 2013
- FT N/A
- Fundamental
- Price
- ENTA $7.84
- FT $7.81
- Analyst Decision
- ENTA Strong Buy
- FT
- Analyst Count
- ENTA 5
- FT 0
- Target Price
- ENTA $20.20
- FT N/A
- AVG Volume (30 Days)
- ENTA 164.6K
- FT 63.0K
- Earning Date
- ENTA 08-11-2025
- FT 01-01-0001
- Dividend Yield
- ENTA N/A
- FT 7.85%
- EPS Growth
- ENTA N/A
- FT N/A
- EPS
- ENTA N/A
- FT N/A
- Revenue
- ENTA $64,806,000.00
- FT N/A
- Revenue This Year
- ENTA N/A
- FT N/A
- Revenue Next Year
- ENTA $1.65
- FT N/A
- P/E Ratio
- ENTA N/A
- FT N/A
- Revenue Growth
- ENTA N/A
- FT N/A
- 52 Week Low
- ENTA $4.09
- FT $5.97
- 52 Week High
- ENTA $13.37
- FT $7.23
- Technical
- Relative Strength Index (RSI)
- ENTA 45.61
- FT 39.67
- Support Level
- ENTA $7.28
- FT $7.86
- Resistance Level
- ENTA $8.86
- FT $8.01
- Average True Range (ATR)
- ENTA 0.53
- FT 0.08
- MACD
- ENTA -0.18
- FT -0.01
- Stochastic Oscillator
- ENTA 29.63
- FT 6.82
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.